Ajanta Pharma Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹1,794 Cr +32.5% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
AP

Ajanta Pharma

Q4 FY26Pharmaceuticals & Biotechnology

Ajanta Pharma Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,422Cr
+21.5% YoY
+3.4% QoQ
Net profit
₹267Cr
+18.7% YoY
−2.6% QoQ
Margin
23%
−2 pp YoY
−5 pp QoQ

What the Q4 FY26 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins slightly down
CapexCapex planned
Price₹3,640
Market cap₹45.5K Cr
P/E40.1

The short version

India business is expected to grow at mid-teens (around 16-18%) in FY27. Ajanta Pharma expects high-teens revenue growth for FY27, approximately 16%-18%.

From Ajanta Pharma's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • India business is expected to grow at mid-teens (around 16-18%) in FY27.
  • Asia business is guided for high double-digit growth next year, recovering from logistics delays.
  • Africa business targeted for high double-digit growth.
  • US generics business to grow at mid-single digit in the coming year after strong 49% growth in FY26.
  • Chronic therapy areas (around 50% of combined Asia and Africa branded generics market) will remain a focus.
  • Gynaecology segment in India showing encouraging progress, expected to contribute meaningfully over next 2-3 years.
  • Nephrology segment in India developing slowly, positive signs but longer gestation.
  • Overall company targeting revenue growth in the high teens (~16-18%) for FY27.

2 more points from Ajanta Pharma's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Ajanta Pharma said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Capital expenditure for FY 2026 stood at Rs. 330 crores, in line with guidance.
  • Ajanta Pharma is embarking upon a new capex cycle to meet continued growth requirements.
  • For FY 2027, capex is expected to increase to around Rs. 400 crores.
  • Of this, Rs. 150 crores is allocated for maintenance, and the balance for new capacity expansion.
  • The company is investing in product range expansion and addition of medical representatives across geographies.

2 more points from Ajanta Pharma's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Ajanta Pharma said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Ajanta Pharma said on order book & pipeline — free account, 30 seconds.

Ajanta Pharma — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Ajanta Pharma Q4 FY26 results — key figures

Ajanta Pharma Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue1,4221,170+21.5%1,375+3.4%
Operating profit (EBITDA)333297+12.1%382-12.8%
Operating margin23%25%-2 pp28%-5 pp
Profit before tax347269+29%359-3.3%
Net profit (PAT)267225+18.7%274-2.6%
EPS (₹)21.3518.03+18.4%21.91-2.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.8K Cr, net profit ₹388 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Ajanta Pharma and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Ajanta Pharma Q4 FY26 results?

India business is expected to grow at mid-teens (around 16-18%) in FY27. Ajanta Pharma expects high-teens revenue growth for FY27, approximately 16%-18%.

What is Ajanta Pharma share price analysis?

Ajanta Pharma currently shows a below-average growth signal. The stock trades at a P/E of 40.1 with a market cap of ₹45,483 Cr. Investors should review the full earnings analysis for detailed insights.

Is Ajanta Pharma planning capital expenditure?

Capital expenditure for FY 2026 stood at Rs. 330 crores, in line with guidance.

Keep Ajanta Pharma on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.